These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 28228262)
1. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262 [TBL] [Abstract][Full Text] [Related]
2. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Li L; Chang W; Yang G; Ren C; Park S; Karantanos T; Karanika S; Wang J; Yin J; Shah PK; Takahiro H; Dobashi M; Zhang W; Efstathiou E; Maity SN; Aparicio AM; Li Ning Tapia EM; Troncoso P; Broom B; Xiao L; Lee HS; Lee JS; Corn PG; Navone N; Thompson TC Sci Signal; 2014 May; 7(326):ra47. PubMed ID: 24847116 [TBL] [Abstract][Full Text] [Related]
3. Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells. Chen S; Chen X; Xie G; He Y; Yan D; Zheng D; Li S; Fu X; Li Y; Pang X; Hu Z; Li H; Tan W; Li J Oncotarget; 2016 Jun; 7(26):40362-40376. PubMed ID: 27246979 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer. Liu K; Graves JD; Lin FT; Lin WC J Biol Chem; 2021; 296():100382. PubMed ID: 33556369 [TBL] [Abstract][Full Text] [Related]
6. Human CTC1 promotes TopBP1 stability and CHK1 phosphorylation in response to telomere dysfunction and global replication stress. Ackerson SM; Gable CI; Stewart JA Cell Cycle; 2020 Dec; 19(24):3491-3507. PubMed ID: 33269665 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy. Massey AJ Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461 [TBL] [Abstract][Full Text] [Related]
8. Norcantharidin inhibits DNA replication and induces mitotic catastrophe by degrading initiation protein Cdc6. Chen S; Wan P; Ding W; Li F; He C; Chen P; Li H; Hu Z; Tan W; Li J Int J Mol Med; 2013 Jul; 32(1):43-50. PubMed ID: 23612688 [TBL] [Abstract][Full Text] [Related]
9. Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation. Liu S; Bekker-Jensen S; Mailand N; Lukas C; Bartek J; Lukas J Mol Cell Biol; 2006 Aug; 26(16):6056-64. PubMed ID: 16880517 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis. Mak JP; Man WY; Ma HT; Poon RY Oncotarget; 2014 Nov; 5(21):10546-57. PubMed ID: 25301733 [TBL] [Abstract][Full Text] [Related]
11. FOXM1 and androgen receptor co-regulate CDC6 gene transcription and DNA replication in prostate cancer cells. Liu Y; Gong Z; Sun L; Li X Biochim Biophys Acta; 2014; 1839(4):297-305. PubMed ID: 24583551 [TBL] [Abstract][Full Text] [Related]
12. Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. García V; Lara-Chica M; Cantarero I; Sterner O; Calzado MA; Muñoz E Oncotarget; 2016 Jan; 7(4):4490-506. PubMed ID: 26683224 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer. Shiota M; Bishop JL; Takeuchi A; Nip KM; Cordonnier T; Beraldi E; Kuruma H; Gleave ME; Zoubeidi A Oncotarget; 2015 Apr; 6(11):9086-98. PubMed ID: 25871401 [TBL] [Abstract][Full Text] [Related]
15. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage. Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079 [TBL] [Abstract][Full Text] [Related]
16. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517 [TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. Hauge S; Naucke C; Hasvold G; Joel M; Rødland GE; Juzenas P; Stokke T; Syljuåsen RG Oncotarget; 2017 Feb; 8(7):10966-10979. PubMed ID: 28030798 [TBL] [Abstract][Full Text] [Related]
18. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells. Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759 [TBL] [Abstract][Full Text] [Related]
19. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors. Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335 [TBL] [Abstract][Full Text] [Related]
20. Cleavage of Cdc6 by caspase-3 promotes ATM/ATR kinase-mediated apoptosis of HeLa cells. Yim H; Hwang IS; Choi JS; Chun KH; Jin YH; Ham YM; Lee KY; Lee SK J Cell Biol; 2006 Jul; 174(1):77-88. PubMed ID: 16801388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]